Emerging studies are sparking significant interest surrounding the medication, a promising dual agonist targeting incretin and glucose-dependent insulinotropic polypeptide. Distinct from existing weight loss therapies , the drug appears to provide more reductions in body fat and enhance glucose outcomes in preliminary tests . Despite more evaluati